focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Whitbread Surges On Costa Coffee Sale

Fri, 31st Aug 2018 10:36

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Whitbread, up 16%. The hospitality firm said it agreed the sale of its Costa Coffee business to US soft drinks giant Coca-Cola Co at an enterprise value of GBP3.90 billion. Whitbread, which also owns the Premier Inn hotel chain, is expecting net proceeds of GBP3.80 billion, and said most of this will be returned to shareholders. The sale, the company continued, will reduce debt and also allow for an increased pension contribution and further expansion of Premier Inn in both the UK and Germany. Whitbread believes a "substantial" premium would have been created by its planned demerger of Costa Coffee, which was announced in April this year. At the time the company had described itself as "committed" to demerging Costa after the coffee chain saw a decline in annual profit.----------FTSE 100 - LOSERS----------Sage Group, down 6.5%. The accounting software provider said Chief Executive Officer Stephen Kelly has stepped down from his role with immediate effect. He is to "remain available to the group" until May 31, 2019. Kelly has been chief executive of Sage for nearly four years since 2014. The FTSE 100 group has started the process to find a new chief executive. Chief Financial Officer Steve Hare has been given the additional post of chief operating officer on an interim basis, giving him full authority to run the business until a new chief executive is appointed. In addition, Sage said it has continued to trade in line with its full-year guidance of 7.0% organic revenue growth and a 27.5% organic operating margin. The group said achieving this guidance is dependent on the closing of several Enterprise Management opportunities in September.----------Evraz, down 1.5%, Glencore, down 1.2%, BHP Billiton, down 0.9%. The commodity stocks were lower amid concerns that the US-Chinese trade dispute may intensify and over metal tariffs. US President Donald Trump said he could move ahead with a plan to impose tariffs on USD200 billion in Chinese imports as early as next week. In addition, Trump also threatened to pull out from the World Trade Organization and called European trade policies "almost as bad as China," raising fresh worries over trade friction.----------FTSE 250 - WINNERS----------Hays, up 6.4%. Shares in the recruiter were rebounding after it expressed uncertainty for its UK market due to economic instability, despite reporting positive results for its recently ended financial year on Thursday. The stock closed down 4.7% on Thursday. ----------FTSE 250 - LOSERS----------Serco Group, down 3.1%. Exane BNP downgraded the outsourcer to Neutral from Outperform.----------OTHER MAIN MARKET AND AIM - WINNERS----------Midatech Pharma, up 31%. The rare disease-focused pharmaceutical company announced positive data from its proof of concept exploratory study for its key oncology drug candidate MTD201. MTD201 Q-Ocreotide is a sustained-release treatment for carcinoid cancer and acromegaly. In a a double-blind exploratory study, the tolerability, pharmacokinetics and growth hormone profiles after a 30 milligram injection in 24 healthy subjects were compared between MTD201 and Novartis AG's Sandostatin LAR. Results from the study indicated that MTD201 produces a safe sustained-release profile of octreotide with growth hormone levels suppressed by an average of 25%, comparable with Sandostatin. Midatech will now seek regulatory approval for MTD201 as an equivalent product of improved product to Sandostatin in preparation for a follow-on trial.----------OTHER MAIN MARKET AND AIM - LOSERS----------FFI Holdings, down 27%. The entertainment industry contract provider said profit halved as costs associated with its recently listing hurt despite revenue jumping on acquisitions. For the year ended March 31, pretax profit halved to USD5.3 million from USD10.3 million the year prior. This was despite revenue rising to USD58.9 million from USD38.8 million the year before. Profit performance was hurt by a sharp rise in administrative and exceptional costs. Administrative expenses rose to USD29.4 million from USD18.9 million the year prior primarily driven by a jump in staff costs. Exceptional costs also rose to USD10.7 million from USD1.9 million the year before which was chiefly related to USD9.5 million in initial public offering costs.----------
More News
29 Jan 2019 16:56

Midatech Pharma To Raise GBP8 Million, Enters Licence Deal (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC on Tuesday said it entered into conditional agreements to raise GBP8 million by way of a subscription for new ordinary shares at 3.85 pence per on of a

Read more
25 Jan 2019 17:18

LONDON MARKET CLOSE: Stocks Mixed As Miners Rise But Vodafone Sinks

LONDON (Alliance News) - Stocks in London finished the week mixed as commodity miners were unable to keep the FTSE 100 in the green with Vodafone dragging the index lower.The FTSE 100 closed down

Read more
25 Jan 2019 10:40

WINNERS & LOSERS SUMMARY: Earthport Gains As Mastercard Out Bids Visa

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 3.2%. UBS raised the Mexican miner to Buy

Read more
25 Jan 2019 09:51

Midatech Pharma Shares Halve Amid Urgent Scramble To Secure Cash

LONDON (Alliance News) - Shares in Midatech Pharma PLC more than halved Friday as it said it is urgently looking to conclude a deal with a strategic investor with cash funds rapidly running the it

Read more
25 Jan 2019 08:35

Midatech seeking cash after FDA feedback

(Sharecast News) - Oncology and rare disease-focussed company Midatech Pharma announced on Friday that it has received feedback from the US Food and Drug Administration (FDA) on the regulatory study for its lead product, 'MTD201 Q-Octreotide'.

Read more
20 Dec 2018 10:12

Midatech inks evaluation agreement with Asian pharma outfit

(Sharecast News) - Pharmaceutical research and development outfit Midatech has inked an agreement with an unnamed company to evaluate its Q-Sphera drug delivery platform.

Read more
1 Nov 2018 11:37

Midatech Pharma Completes Sale Of US Business To Kanwa Holdings

LONDON (Alliance News) - Immunotherapy-focused pharmaceutical company Midatech Pharma PLC said on Thursday it has completed sale of Midatech Pharma US Inc to Kanwa Holdings LP, owned by Baring for

Read more
8 Oct 2018 15:59

UK Shareholder Meetings Calendar - Next 7 Days

Tuesday 9 Octoberno events scheduledWednesday 10 October Whitbread (sale of Costa

Read more
27 Sep 2018 10:44

Midatech Narrows Loss, Agrees Sale Of US Unit For Up To USD19 million

LONDON (Alliance News) - Midatech Pharma PLC reported a narrowed interim loss as it planned to divest its US unit to become a "pure play biotech company".Total revenue for the six

Read more
31 Aug 2018 09:38

Midatech Pharma Shares Rise Following Positive MTD201 Trial Data

LONDON (Alliance News) - Shares in Midatech Pharma PLC jumped on Friday following positive data from its proof of concept exploratory study for its key oncology drug candidate MTD201.Shares

Read more
25 Jul 2018 12:26

Midatech Expects 16% Half-Year Revenue Increase Amid Confident Outlook

LONDON (Alliance News) - Midatech Pharma PLC said Wednesday it expects to meet market expectations for 2018 after increasing half-year revenue year-on-year.For the six months to June 30, it

Read more
25 Jul 2018 10:15

Midatech Pharma 'on track' for first half

(Sharecast News) - Cancer-focused pharmaceutical company Midatech Pharma has remained "on track" to deliver financial results for the first half of the calendar year in line with market expectations, and was still exploring options about how to meet its cash flow needs.

Read more
25 May 2018 12:23

Midatech Pharma Commences First In-Human Study Of Brain Cancer Drug

LONDON (Alliance News) - Midatech Pharma PLC said Friday it started the first in-human study of childhood brain cancer drug MTX110.The study will be a combined phase 1 and phase 2 clinical

Read more
3 May 2018 12:14

MidaTech Pharma "Not Aware Of Any Reason" For Sharp Share Price Drop

LONDON (Alliance News) - Midatech Pharma PLC said Thursday that it is "not aware of any reason" behind the sharp drop in its share price.Midatech shares were down 22% at 35.80 its

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.